Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.

Abstract

This is a summary of a research study (known as a clinical trial) called CROWN. The study tested two medicines called lorlatinib and crizotinib in participants with untreated non-small cell lung cancer that had spread to other parts of their body. All those who took part had changes in a gene called ALK, which is involved in cell growth. In total, 296 participants from 23 countries took part. Half the participants took lorlatinib and half took crizotinib. After participants started taking lorlatinib or crizotinib, they were checked regularly to see if their tumors had grown or spread to other parts of their body (known as tumor progression) and to monitor any side effects. After 1 year of treatment, the participants who took lorlatinib were twice as likely to be alive with no tumor growth as the participants who took crizotinib. More participants who took lorlatinib had cancer that shrank (76%) compared with the participants who took crizotinib (58%). This was also true of the participants whose cancer had spread to their brain. The most common side effects in participants who took lorlatinib were increases in the amount of cholesterol and triglycerides (a type of fat) in their blood, swelling, weight gain, nerve damage, unclear thoughts, and diarrhea. Among the participants who took crizotinib, the most common side effects were diarrhea, feeling like you want to throw up, sight problems, swelling, vomiting, changes in liver function, and feeling tired. Overall, the CROWN study showed that fewer participants with advanced ALK+ non-small cell lung cancer died or had tumor growth with lorlatinib compared with crizotinib treatment. ClinicalTrials.gov NCT number: NCT03052608.

• Authors: Benjamin J Solomon, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna Maria Calella, Gerson Peltz, Alice T Shaw
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 34 Pg. 4649-4656 (Dec 01 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 34585621 (Publication Type: Journal Article, Comment)

Chemical References

• Aminopyridines
• Lactams
• Pyrazoles
• Crizotinib
• Anaplastic Lymphoma Kinase
• lorlatinib

Topics

• Aminopyridines
• Anaplastic Lymphoma Kinase
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• Crizotinib
• Humans
• Lactams
• Language
• Lung Neoplasms (drug therapy, genetics)
• Pyrazoles